People · Operator
Named in public records as an officer, director or promoter · active 2013–2017 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cidara Therapeutics, Inc. | — | Biotechnology | Series D+ | $349.1M | $2.8B | 2014 |
| Expansion Therapeutics, Inc. | — | Pharmaceuticals | Series C | $78.3M | $1.1B | 2016 |
| Variation Biotechnologies (US), Inc. | — | Biotechnology | Series A | $17.1M | $54.2M | 2013 |
Kevin Forrest at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Forrest on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| SCOTT ROCKLAGE | 3 | 9 |
| Steven Gillis | 1 | 23 |
| Steve Gillis | 1 | 13 |
| Patrick Heron | 1 | 11 |
| Nina Kjellson | 1 | 11 |
| Jason Hafler | 1 | 6 |
| Paul Stone | 1 | 5 |
| Scott M. Rocklage | 1 | 4 |
| Jeff Baxter | 1 | 4 |
| Steve Elms | 1 | 4 |
| Jeffrey Stein | 1 | 4 |
| Jeffrey Leiden | 1 | 4 |
| Michael Steinmetz | 1 | 4 |
| Theodore R. Schroeder | 1 | 4 |
| David E. Anderson | 1 | 3 |
| Dirk Thye | 1 | 3 |
| Daniel D. Burgess | 1 | 3 |
| Egidio Nascimento | 1 | 3 |
| Kevin Judice | 1 | 3 |
| Yujiro Hata | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.